The long-term objective of the Pharmacology Shared Resource is to provide critical pharmacologic support, services and expertise for Cancer Center investigators engaged in the development and evaluation of anticancer agents.
The specific aims of the Shared Resource are to provide the necessary services and expertise for: 1) the conduct of clinical pharmacokinetic studies performed through the vigorous NCI-funded Phase I and Phase II clinical trials programs in the Cancer Center, 2) for the conduct of pharmacogenetic studies performed in conjunction with appropriate early clinical trials and 3) for the conduct of preclinical pharmacology studies in support of Cancer Center investigator research. To accomplish these aims, the Shared Resource has state of the art capabilities and expertise for the sensitive and specific analysis of drugs and their metabolites in biological specimens, for structure elucidation and pharmacologic characterization of drug metabolites, for the conduct of clinical and preclinical pharmacokinetic studies using those assay methodologies, for the detailed analysis of pharmacokinetic data and for the conduct of pharmacogenetic studies using validated assays for determination of allelic variants of genes related to drug response. In addition, Shared Resource key personnel consult with Cancer Center investigators in the design of studies and the analysis and interpretation of pharmacologic data obtained in those studies. During the current funding period, the Shared Resource has conducted approximately 30 clinical pharmacology protocol-based studies in conjunction with Phase I and Phase II clinical trials encompassing pharmacokinetic and pharmacogenetic components. The Shared Resource also provided preclinical pharmacologic support for eight Cancer Center investigator-initiated laboratory projects either for grantfunded studies or in preparation for grant submissions.
|Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30|
|Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36|
|Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42|
|Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90|
|Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56|
|Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9|
|McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51|
|Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of MÃ¼llerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31|
|Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9|
|Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44|
Showing the most recent 10 out of 948 publications